Chimiothérapie d’induction des lymphomes malins non hodgkiniens

Publisher Website
Google Scholar
Abstract
Two types of chemotherapy were compared in a randomized trial to treat non-Hodgkin malignant lymphomas; 66 patients were included in this study, but only 40 were evaluable after a histologic review of all cases. Treatment was an association of cyclophosphamide, vincristine, prednisone and doxorubicine or VM 26 [5R-(5.alpha.,5.alpha.B,8a.alpha.,9.beta.)]-5,8,8a,9-tetrahydro-5-1(4-hydroxy-3,5-dimethoxyphenyl)-9-[[4,6-O-(2-thienylmethylene)-.beta.-D-glucopyranosyl]oxy]furo[3'',4'',6,7]-naphtho[2,3-d]-1,3-dioxol-6(5aH)-one]. Patients received only 1 induction chemotherapy course during 15-20 days. Results were evaluated immediately at the end of the course. Side-effects were mild. Efficacy was about the same with the 2 protocols: 35 patients out of 40 experienced a remission of more than 50% (8 experienced a complete remission). These results are better than previous ones obtained with cyclophosphamide, vincristine and prednisone only. This type of treatment was well tolerated, quickly efficient and useful before treating patients with radiotherapy or long-term chemotherapy.

This publication has 0 references indexed in Scilit: